dementia

Health Usha Lee McFarling

Where caregiving is a family affair, Alzheimer’s places a heavy burden on children and spouses

Health Usha Lee McFarling

On the Texas-Mexico border, a bold plan to diversify Alzheimer’s research takes shape

Biotech Damian Garde and Adam Feuerstein

Alzheimer’s treatment slowed cognitive decline in closely watched clinical trial

Health Jonathan Wosen

Daily multivitamins improved the brain function of seniors in a trial — but plenty of questions remain

Biotech Jason Mast

How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy

D.C. Diagnosis Elissa Welle

Democrats’ TGIF moment, pathologists defend their turf, & Biogen’s back at the FDA’s doorstep

Health Jonathan Wosen

From buzzy biomarkers to learning from failure: 3 takeaways from the Alzheimer’s Association International Conference

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer’s data

The Readout LOUD Damian Garde and Adam Feuerstein

Listen: VC malaise, FDA confusion, & yet another Alzheimer’s debate

Biotech Adam Feuerstein

The biotech scorecard for the third quarter: 18 stock-moving events to watch

Pharma Adam Feuerstein

A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease

First Opinion Howard M. Fillit

It’s time to move past Aduhelm and focus on a broader Alzheimer’s drug pipeline

Politics Lev Facher

Key Senate committee proposes a council to ensure FDA better coordinates on accelerated approvals

In the Lab Megan Molteni

Transfusion of brain fluid from young mice is a memory-elevating elixir for old animals

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Succession at Biogen, surprises at Vertex, & a potential superspreader dinner

First Opinion Anand Kumar

Exploitation in the name of biomedical innovation cannot be tolerated

D.C. Diagnosis Nicholas Florko

The FDA’s Rob Califf on importing drugs from Canada, on Aduhelm, and on opioids

Insurance Bob Herman

UnitedHealthcare restricts coverage of Aduhelm, following Medicare

Biotech Adam Feuerstein and Damian Garde

Biogen board slashes CEO’s bonus as Aduhelm sales and overall business struggle

Politics Nicholas Florko

Medicare’s Brooks-LaSure expects restrictions on accelerated approval drugs, like those for Aduhelm, to be ‘very rare’

D.C. Diagnosis Nicholas Florko

The next battle in the never-ending war over Aduhelm

Politics Nicholas Florko

Will Biogen sue Medicare over its restrictions on the Alzheimer’s drug, Aduhelm? And other big legal questions about the decision

First Opinion Dennis J. Selkoe and Jeffrey Cummings

CMS made the wrong decision on Aduhelm. But there might be a silver lining

First Opinion John N. Mafi and Catherine Sarkisian

Medicare got it right: Unproven Alzheimer’s drug would have threatened the financial stability of 60 million Americans

Politics Rachel Cohrs

Medicare finalizes its restrictions on new Alzheimer’s drug, despite pressure from drugmakers